Table 2. LS Mean (SE) Change from Baseline to Week 4 in Efficacy Measures.
|
Placebo (N=110) |
Dasotraline 4 mg/day (N=114) |
Dasotraline 8 mg/day (N=107) |
||||||
|---|---|---|---|---|---|---|---|---|
| LS mean change (SE) | 95% CI | LS mean change (SE) | 95% CI | P-value | LS mean change (SE) | 95% CI | P-value | |
| ADHD RS-IV | ||||||||
| Total score | −9.7 (1.1) | (−11.8, −7.6) | −12.4 (1.1) | (−14.5, −10.3) | 0.076a | −13.9 (1.2) | (−16.3, −11.5) | 0.019a |
| Hyperactivity/Impulsivity score | −4.1 (0.5) | (−5.2, −3.1) | −5.4 (0.5) | (−6.5, −4.3) | 0.094 | −5.9 (0.6) | (−7.2, −4.7) | 0.027 |
| Inattentiveness score | −5.6 (0.6) | (−6.9, −4.4) | −7.0 (0.6) | (−8.3, −5.7) | 0.125 | −8.0 (0.7) | (−9.4, −6.5) | 0.016 |
| CGI-Severity score | −0.7 (0.1) | (−1.0, −0.5) | −1.1 (0.1) | (−1.3, −0.9) | 0.021 | −1.1 (0.1) | (−1.4, −0.9) | 0.013 |
| WRAADDS total score | −9.0 (1.0) | (−10.9, −7.0) | 11.0 (1.0) | (−13.0, −9.0) | 0.147 | −11.9 (1.2) | (−14.2, −9.6) | 0.056 |
a
P-value was adjusted for multiple comparisons using the Hochberg procedure.